Financial Performance - The company's operating revenue for Q1 2024 was ¥290,485,885.02, representing a 3.20% increase compared to ¥281,477,110.37 in the same period last year[4] - Net profit attributable to shareholders for Q1 2024 was ¥65,768,245.08, up 12.41% from ¥58,506,301.86 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥63,270,085.93, reflecting a 15.41% increase from ¥54,823,279.11 year-on-year[4] - Total operating revenue for Q1 2024 was CNY 290,485,885.02, an increase of 3.6% compared to CNY 281,477,110.37 in Q1 2023[29] - Net profit for Q1 2024 reached CNY 62,711,013.40, representing a 9.4% increase from CNY 57,223,058.34 in Q1 2023[31] - Earnings per share for Q1 2024 were CNY 0.1317, compared to CNY 0.1169 in Q1 2023, reflecting a growth of 12.8%[32] Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of ¥16,674,003.66, a decline of 63.63% compared to the previous year's outflow of ¥10,190,148.66[4] - Cash flow from operating activities for Q1 2024 was negative CNY 16,674,003.66, worsening from negative CNY 10,190,148.66 in Q1 2023[34] - The company's cash and cash equivalents decreased to CNY 225,634,229.06 from CNY 259,036,352.33, a decline of about 12.91%[24] - The ending balance of cash and cash equivalents was 224,636,290.01, a decrease from the beginning balance of 258,038,745.01[37] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,251,478,334.71, an increase of 4.20% from ¥3,120,279,712.38 at the end of the previous year[4] - Total liabilities as of Q1 2024 were CNY 1,994,900,845.39, up from CNY 1,815,658,166.50 in Q1 2023[27] - Total equity decreased to CNY 1,256,577,489.32 in Q1 2024 from CNY 1,304,621,545.88 in Q1 2023[27] - The company reported a significant increase in long-term borrowings, which rose to CNY 859,472,383.35 from CNY 749,567,882.38 year-over-year[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,900[11] - The company repurchased a total of 32,882,057 shares, accounting for 6.44% of the total share capital, with a total expenditure of CNY 406,909,004.85[21] - The company’s controlling shareholder increased their stake by acquiring 7,410,000 shares, representing 1.45% of the total share capital, with an investment of CNY 80,141,558[22] - A total of 861,300 restricted stocks were released from restrictions, with 51 individuals qualifying for the release[16] Research and Development - The company experienced a 63.03% increase in development expenditures, attributed to new R&D investments by subsidiaries[8] - Research and development expenses for Q1 2024 amounted to CNY 16,842,823.76, an increase from CNY 15,338,908.50 in the previous year[29] Financial Expenses and Other Costs - The company reported a 52.51% increase in financial expenses due to a rise in short-term borrowings[8] - Total operating costs for Q1 2024 were CNY 210,680,477.20, up from CNY 209,177,109.93 in the same period last year[29] Contract Liabilities - Contract liabilities increased by 98.72%, primarily due to an increase in advance payments received by subsidiaries[8] Non-Current Assets - The total non-current assets amounted to CNY 2,294,557,556.86, up from CNY 2,229,964,609.49, indicating an increase of approximately 2.91%[25]

证券代码：000534 证券简称：万泽股份 公告编号：2024-036 万泽实业股份有限公司 关于公司 2021 年股权激励计划限制性股票 第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2021 年股权激励计划首次授予限制性股票第一个解除限售期解 除限售条件已经成就，符合解除限售条件的激励对象共计 139 名，解除限售的 限制性股票数量为 2,418,500 股，占公司当前总股本的 0.4736%。 2. 本次解除限售的限制性股票解除限售上市流通日为 2024 年 4 月 15 日。 万泽实业股份有限公司（以下简称"公司"、"本公司"）于 2024 年 3 月 28 日召开第十一届董事会第三十三次会议，审议通过了《关于公司 2021 年股权 激励计划限制性股票第一个解除限售期解除限售条件成就的议案》，同意公司 办理 2021 年股权激励计划限制性股票第一个解除限售期解除限售事宜，现将 相关内容公告如下： 一、公司 2021 年股权激励计划已履行的相关审批程序 （一）2021 年 11 月 ...

万泽股份第十一届董事会第三十三次会议资料 万泽实业股份有限公司 对会计师事务所 2023 年度履职情况评估报告暨 审计委员会履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》《国有企业、上市公司选聘会计师事务所管理办法》和《公司章 程》等规定和要求，万泽实业股份有限公司（以下简称"公司"）董事会审 计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会对会计师 事务所 2023 年度履职评估及董事会审计委员会履行监督职责的情况汇报如 下： 一、2023 年年审会计师事务所履职情况 公司于 2023 年 6 月 30 日召开了 2022 年度股东大会，审议通过了《关 于续聘大华会计师事务所（特殊普通合伙）为公司 2023 年度审计机构的议 案》，同意公司续聘大华会计师事务所（特殊普通合伙）（以下简称"大华会 计师事务所"）为公司 2023 年度审计机构。 万泽股份第十一届董事会第三十三次会议资料 2023 年 12 月 31 日与财务报表相关的内部控制的建立和执行情况进行了审 核，同时对 ...

万泽实业股份有限公司 关于回购公司股份的进展公告 证券代码：000534 证券简称：万泽股份 公告编号:2024-035 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 | | --- | | 虚假记载、误导性陈述或重大遗漏。 | 万泽实业股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召开 第十一届董事会第二十三次会议，审议通过《关于回购公司股份方案的议 案》，同意公司以自有资金通过集中竞价的方式回购部分已发行的人民币普 通股（A 股）用于股权激励计划或员工持计划，回购的资金总额不低于人民 币 1.5 亿元（含）且不超过人民币 3 亿元（含），回购价格不超过人民币 16.00 元/股（含），回购股份实施期限为自公司董事会审议通过回购股份方案之日 起不超过 12 个月。具体情况详见公司于 2023 年 8 月 29 日披露的《关于回 购股份方案的公告》（公告编号：2023-055）。 为进一步维护全体股东权益，增强投资者信心，同时根据中国证监会 《上市公司股份回购规则（2023 年修订）》等的有关规定，公司于 2023 年 12 月 28 日召开第十一届董事会第三十次会议 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Views - The company has achieved a revenue of 980 million yuan in 2023, representing a year-on-year increase of 23.6%, and a net profit attributable to shareholders of 180 million yuan, up 73.6% year-on-year [2][3]. - The company is entering a production phase for multiple products, with a strong pipeline of 123 new products under development, ensuring long-term growth potential [2]. - The pharmaceutical segment is steadily growing, with high-temperature alloy revenue increasing by 52% [2]. - The company has optimized its expense ratio while increasing R&D investment, with R&D expenses rising by 38.7% to 110 million yuan [2]. - The company is positioned as a leader in the micro-ecological live bacteria sector in China and has developed significant capabilities in high-temperature alloys and components [2]. Financial Performance Summary - In Q4 2023, the company achieved a revenue of 250 million yuan, a year-on-year increase of 19.7%, and a net profit of 54 million yuan, up 782.3% year-on-year [2]. - The gross margin for 2023 decreased by 2.6 percentage points to 74.2%, while the net margin increased by 5.9 percentage points to 19.2% [2]. - The company expects to achieve net profits of 270 million, 360 million, and 460 million yuan for the years 2024, 2025, and 2026, respectively, with corresponding PE ratios of 23x, 18x, and 14x [2].

Dividend Distribution - The company plans to distribute a cash dividend of 1.2 CNY per 10 shares (including tax) to all shareholders, with no bonus shares issued[5]. - The total cash dividend, including other methods, amounts to 333,727,925.06 RMB, representing 100% of the total profit distribution[145]. - The cash dividend distribution accounts for 32.48% of the net profit attributable to the parent company for the year 2023[147]. - The company has established a three-year dividend plan (2021-2023) to enhance the dividend mechanism and protect minority shareholders' rights[143]. - The company has ensured that minority shareholders have sufficient opportunities to express their opinions regarding the profit distribution plan[144]. - The company plans to distribute cash dividends amounting to at least 10% of the annual distributable profits, provided the earnings per share exceed 0.05 CNY[174]. - The company has committed to a cumulative cash distribution of profits not less than 30% of the average annual distributable profits over the next three years[174]. Shareholder Structure - As of December 31, 2023, Wanze Group holds 198,608,136 shares of the company, representing a 38.82% stake, making it the controlling shareholder[19]. - The company has not reported any changes in its controlling shareholder since the last major transfer of shares in November 2005[19]. - The company reported a complete independence in operations from its controlling shareholders, with no direct or indirect interference in business operations[110]. Financial Performance - The company's operating revenue for 2023 was ¥981,439,362.70, representing a 23.63% increase compared to ¥793,843,031.64 in 2022[21]. - Net profit attributable to shareholders for 2023 was ¥176,554,971.16, a significant increase of 73.54% from ¥101,719,117.75 in 2022[21]. - The net profit after deducting non-recurring gains and losses was ¥104,087,060.80, up 28.99% from ¥80,672,086.22 in the previous year[21]. - The company's cash flow from operating activities decreased by 51.39% to ¥94,738,878.02 from ¥194,886,261.83 in 2022[21]. - Basic earnings per share increased by 75.80% to ¥0.3574 in 2023, compared to ¥0.2033 in 2022[21]. - Total assets at the end of 2023 reached ¥3,120,279,712.38, marking a 28.15% increase from ¥2,434,804,891.48 at the end of 2022[21]. Business Focus and Operations - The company has undergone a change in its main business focus, shifting from power generation to the research, manufacturing, and sales of high-temperature alloys and related technical services[19]. - The company is the only private enterprise in China capable of full-process research and development of high-temperature alloy materials, with applications in various industries[31]. - The company has established a core technology system for ultra-high purity nickel-based superalloy smelting, primarily producing superalloy materials for high-temperature components[38]. - The company has developed advanced technologies for the production of high-temperature superalloy powders and precision cast blades, with products already in mass production for various aerospace and gas turbine applications[39]. - The company is focusing on the industrialization of high-temperature alloy components, aiming to meet the growing demand in aerospace and energy sectors[68]. Research and Development - The company has applied for 12 invention patents in 2023, with 11 already granted, focusing on probiotic research and development[42]. - Research and development expenses increased by 38.75% to ¥105.97 million, attributed to enhanced investment in R&D initiatives[66]. - The company has a high-level R&D team in the field of high-temperature alloys, with over 40% of its personnel holding master's or doctoral degrees[38]. - The company aims to develop approximately 10 new probiotic strains annually through its probiotic strain library project, enhancing product development capabilities[67]. - The establishment of a database for functional probiotic strains has been completed, enhancing the company's research and development capabilities[67]. Market and Product Development - The market demand for probiotic products is rapidly growing due to increasing public health awareness and an aging population in China[30]. - The company launched new probiotic products, including "Three-Probiotic Powder" and "Today Probiotic™" dietary supplements, expanding its product line[33]. - The company has built a comprehensive marketing system covering prescription drugs, OTC products, and health foods, collaborating with over 3,000 hospitals and 100,000 pharmacies nationwide[35]. - The company’s "Jin Shuangqi®" and "Ding Junsheng®" products were retained in the National Medical Insurance Directory (2023 version), enhancing their market access[43]. Governance and Management - The company’s board of directors and management team are fully independent, with all senior management receiving compensation directly from the company[112]. - The company has maintained a stable management team, with most members having served for several years, ensuring continuity in leadership[117][118]. - The company has a structured remuneration decision-making process involving a compensation committee that proposes plans for board approval[124]. - The company’s independent directors provided objective opinions on major matters discussed in board meetings, ensuring effective governance[132]. Financial Management and Audit - The company has established a robust financial management system, maintaining independent accounting and banking operations[112]. - The internal control evaluation report indicated that the company maintained effective financial reporting internal controls in all material aspects as of December 31, 2023[160]. - The company has established a comprehensive internal control system to ensure compliance with legal regulations and enhance operational efficiency[156]. - The company has appointed Shenzhen Dahua International Accounting Firm as its auditor for the 2023 fiscal year, with an audit fee of 1.2 million yuan[180]. Future Outlook - The pharmaceutical industry is expected to gradually improve in 2024, driven by technological innovation and domestic substitution, with a focus on high-quality and healthy development[94]. - The high-temperature alloy industry is anticipated to experience rapid growth due to national support and increasing demand in aerospace, power, and other key sectors[95]. - The company aims to advance its micro-ecological probiotic products and high-temperature alloy business simultaneously in 2024, leveraging opportunities from the new technological revolution[96]. Compliance and Risk Management - The company has committed to ensuring the independence of its personnel, assets, finances, institutions, and business operations[170]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[164]. - The company actively maintains a governance structure that protects the interests of shareholders, particularly minority shareholders[166].

第一条 公司应着眼于长远和可持续发展，兼顾业务发展需要和股东 稳定回报，综合考虑企业经营发展实际、股东要求和意愿、社会资金成本、 外部融资环境等因素，充分听取股东特别是中小股东的意愿，建立对投资 者持续、稳定、科学的回报机制，并从制度上对股利分配作出安排，以保 障股利分配政策的连续性和稳定性。 第二条 公司分红规划充分考虑和听取股东（特别是公众投资者）、 独立董事的意见，确保现金分红形式的合理投资回报。 第三条 公司未来三年（2024-2026年）的具体分红规划： 1、公司应实施积极的利润分配办法，确保投资者的合理投资回报。 2、在公司年度实现的可分配利润为正数，且每股收益大于0.05元的情 况下，公司每一年度应当采取现金或现金和股票相结合或者法律允许的其 他方式分配利润，利润分配不得超过累计可分配利润的金额，不得损害公 司的可持续发展能力。 3、在满足公司正常生产经营的资金需求且符合利润分配条件的前提 下，坚持现金分红为主的原则，公司每年以现金方式分配的利润不少于当 年实现的可分配利润的百分之十。如因重大投资计划或重大现金支出等事 项董事会未提出现金分红预案或年度现金分红比例低于当年实现的可分 配利润的百分 ...

万泽实业股份有限公司 审计报告 大华国际审字第 2400153 号 深 圳 大 华 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Shenzhen Dahua International CPAs, LLP 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn） 进行查验 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn） 进行查验 万泽实业股份有限公司 审计报告及财务报表 (2023 年 1 月 1 日至 2023 年 12 月 31 日止 ) | | 自 | 求 | 页 次 | | --- | --- | --- | --- | | 1 | 审计报告 | | 1-6 | | | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | ...

万泽股份第十一届董事会第三十三次会议资料 （二）独立性说明 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何 职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不 存在妨碍本人进行独立客观判断的关系，不存在影响独立董事独立性的情 况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 1 号—主板上市公司规范运作》等法律、法规、规范性文件及《公 司章程》《公司独立董事制度》中关于独立董事独立性的相关要求。 二、独立董事年度履职概况 李丘林，男，1974 年 7 月出生，博士研究生学历。历任清华大学深圳 研究生院讲师、副教授、博导，现任清华大学深圳国际研究生院教授、博导， 2019 年 3 月起任公司独立董事。 作为万泽实业股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》、《关于在上市公司建立独立董事制度的指导意见》、《关于 加强社会公众股股东权益保护的若干规定》等法律法规和《公司章程》、《公 司独立董事制度》的规定和要求，在 2023 年度的工作中，忠实履行职责， 积极出席公司相关会议，认真审议董事会各项议案，充分发挥独立董事的独 立作用，维 ...

证券代码：000534 证券简称：万泽股份 公告编号:2024-030 万泽实业股份有限公司 关于拟向相关金融机构申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万泽实业股份有限公司（以下简称"公司"）第十一届董事会第三十三 次会议审议通过《关于拟向相关金融机构申请综合授信额度的议案》，具体 情况如下： | 序号 | 公司名称 | 授信额度 | | --- | --- | --- | | 1 | 万泽实业股份有限公司 | 6 亿元 | | 2 | 深圳市万泽中南研究院有限公司 | 亿元 5 | | 3 | 深圳市万泽精密铸造科技有限公司 | 亿元 3 | | 4 | 上海万泽精密铸造有限公司 | 8 亿元 | | 5 | 深圳市深汕特别合作区万泽精密科技有限公司 | 10 亿元 | | 6 | 内蒙古双奇药业股份有限公司 | 亿元 8 | | 7 | 深圳市新万泽医药有限公司 | 3 亿元 | | 8 | 珠海市万泽生物医药有限公司 | 12 亿元 | | | 合计 | 亿元 55 | 上述授信额度不等于公司的实际融资金额，实际融资金额 ...